Antimicrobial resistance (AMR) is a global health threat and AMR infections are a major driver of mortality and reduced quality of life.1 In 2021, an estimated 4.71 million deaths were associated with AMR. Without effective tools to avert AMR mortality, this figure could rise to 8.22 million by 2050.2 Resistant infections also increase the cost per hospital admission and could have a global economic impact, with one model estimating economic losses of US$1.7 trillion annually if drug resistance is not tackled.3
AMR is a growing concern in wound care due to reported inappropriate use of antimicrobials including antibiotics.4 Sorbact® Technology dressings can form a valuable part of your antimicrobial stewardship (AMS) strategy by reducing the microbial burden without using antimicrobial agents.10
The new international guideline on AMS in wound care4 places* microbial-binding dressings, such as Sorbact Technology dressings, at the forefront of wound care.
This guideline lays out four evidence-based, practical pathways that champion infection prevention, early intervention and the first-line use of microbial-binding dressings to help drive more consistent, responsible wound care.4
*Sorbact Technology dressings utilise a DACC™-coated surface.
Infection can be prevented by intervening prophylactically to reduce microbial burden in the early stages of the wound infection continuum.4 The new International Guideline on AMS in wound care4 recommends* microbial-binding dressings as first-line therapy for early intervention and treatment in hard-to-heal wounds (HtHWs) such as diabetes related foot ulcers (DRFUs) and venous leg ulcers (VLUs)4.
Cutimed Sorbact is designed with Sorbact Technology that helps prevent and treat wound infection5,6 across patients of all ages^.6,7,8
* following local policy and where clinically appropriate
^ Note precautions for Cutimed® Sorbact® Gel/Sorbact® Gel Compress / Cutimed® Sorbact® Hydro in IFU.
Clinical pathways for HtHWs, DRFUs and VLUs, provided in the International Guideline on AMS in wound care4, support AMS at key clinical decision points in wound care: assessing symptoms and presence of infection; considering the need for dressings; and evaluating progress towards wound healing.4 Implementing such clinical pathways comes with a clear rationale – helping prevent the development of infection, reducing AMR, and helping improve patient outcomes.
Cutimed Sorbact, designed with Sorbact Technology, is a microbial-binding dressing based on physical interactions between the dressing and wound microbes. Bacteria irreversibly bind to the dressing surface to reduce bioburden and support wound healing.10
As antimicrobial agents are not released, the development of bacterial or fungal resistance is not expected.10 Sorbact Technology dressings support AMS strategies9 and may reduce the need for antibiotics.11
Infection can be prevented by intervening prophylactically to reduce microbial burden in the early stages of the wound infection continuum.4 The new International Guideline on AMS in wound care4 recommends* microbial-binding dressings as first-line therapy for early intervention and treatment in hard-to-heal wounds (HtHWs) such as diabetes related foot ulcers (DRFUs) and venous leg ulcers (VLUs)4.
Cutimed Sorbact is designed with Sorbact Technology that helps prevent and treat wound infection5,6 across patients of all ages^.6,7,8
* following local policy and where clinically appropriate
^ Note precautions for Cutimed® Sorbact® Gel/Sorbact® Gel Compress / Cutimed® Sorbact® Hydro in IFU.
In vitro tests showed that Cutimed Sorbact DACC™-coated bacteria-binding wound dressing was able to inhibit the growth of all the World Health Organization (WHO) priority pathogens tested12,13:
